ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet
Categories of resistance: MDR, XDR, PDR, UDR, and (new!) DTR
Lessons in Discovery from Lynn Silver + Pro-con on alternatives to antibiotics
Lancet: 10-20-30 targets to address AMR by 2030
UK to expand NHS Subscription Pilot! Consultation Period launches
Plazomicin (Achaogen) financial post-mortem: #PassPASTEUR
FDA and EMA regulatory updates / Fireside chat during the 4th AMR Conference
News from Davos 2020: Some positive signs, but overall a fragile antibiotic market at a tipping point
IDSA White Paper on developing narrow-spectrum antimicrobials + editorial by G. Drusano
Non-traditional antibiotics: A pipeline review and an analysis of key development challenges
FDA Workshop: Animal models in support of narrow-spectrum agents for A. baumannii and P. aeruginosa
Plazomicin EU marketing application is withdrawn: Near zero market value of newly approved antibacterials
Assessing antibiotic value: DTR, fire extinguishers, and a view from Australia
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet